These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 34185564

  • 1. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
    Butler K, Anderson SJ, Hayward O, Jacob I, Punekar YS, Evitt LA, Oglesby A.
    J Manag Care Spec Pharm; 2021 Jul; 27(7):891-903. PubMed ID: 34185564
    [Abstract] [Full Text] [Related]

  • 2. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP.
    Clin Infect Dis; 2016 Mar 15; 62(6):784-91. PubMed ID: 26658053
    [Abstract] [Full Text] [Related]

  • 3. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.
    Colson A, Chastek B, Gruber J, Majethia S, Zachry W, Mezzio D, Rock M, Anderson A, Cohen JP.
    J Manag Care Spec Pharm; 2024 Aug 15; 30(8):817-824. PubMed ID: 39088337
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.
    J Med Econ; 2015 Aug 15; 18(10):763-76. PubMed ID: 25934146
    [Abstract] [Full Text] [Related]

  • 5. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
    Tremblay G, Chounta V, Piercy J, Holbrook T, Garib SA, Bukin EK, Punekar YS.
    Value Health Reg Issues; 2018 Sep 15; 16():74-80. PubMed ID: 30296624
    [Abstract] [Full Text] [Related]

  • 6. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, Santos J, Omar M, Gálvez C, Sequera S, Jesús SE, Téllez F, Fernández E, García C, Pasquau J.
    Medicine (Baltimore); 2019 Aug 15; 98(32):e16813. PubMed ID: 31393412
    [Abstract] [Full Text] [Related]

  • 7. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA, Miller S, Childs-Kean LM.
    Ann Pharmacother; 2020 Dec 15; 54(12):1252-1259. PubMed ID: 32517480
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
    Osiyemi O, De Wit S, Ajana F, Bisshop F, Portilla J, Routy JP, Wyen C, Ait-Khaled M, Leone P, Pappa KA, Wang R, Wright J, George N, Wynne B, Aboud M, van Wyk J, Smith KY.
    Clin Infect Dis; 2022 Sep 29; 75(6):975-986. PubMed ID: 35079789
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
    van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, Routy JP, Wyen C, Ait-Khaled M, Nascimento MC, Pappa KA, Wang R, Wright J, Tenorio AR, Wynne B, Aboud M, Gartland MJ, Smith KY.
    Clin Infect Dis; 2020 Nov 05; 71(8):1920-1929. PubMed ID: 31905383
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
    Suárez-García I, Alejos B, Hernando V, Viñuela L, Vera García M, Rial-Crestelo D, Pérez Elías MJ, Albendín Iglesias H, Peraire J, Tiraboschi J, Díaz A, Moreno S, Jarrín I, Cohort of the Spanish HIV/AIDS Research Network (CoRIS).
    J Antimicrob Chemother; 2023 Jun 01; 78(6):1423-1432. PubMed ID: 37099559
    [Abstract] [Full Text] [Related]

  • 11. Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.
    Priest J, Germain G, Laliberté F, Duh MS, Mahendran M, Fakih I, Oglesby A.
    Infect Dis Ther; 2023 Aug 01; 12(8):2117-2133. PubMed ID: 37552426
    [Abstract] [Full Text] [Related]

  • 12. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
    Giacomelli A, Conti F, Pezzati L, Oreni L, Ridolfo AL, Morena V, Bonazzetti C, Pagani G, Formenti T, Galli M, Rusconi S.
    BMC Infect Dis; 2021 Jun 22; 21(1):595. PubMed ID: 34157984
    [Abstract] [Full Text] [Related]

  • 13. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
    Evitt LA, Nanji S, Grove RA, Okoli C, van Wyk J, Snedecor SJ.
    AIDS Res Ther; 2023 Mar 22; 20(1):17. PubMed ID: 36949442
    [Abstract] [Full Text] [Related]

  • 14. Cost-Effectiveness of Juluca for Human Immunodeficiency Virus Infection Treatment in Virologically Suppressed Adults in Taiwan.
    Anderson SJ, Hsu CY, Ou HT, Ko NY, Yang CT, Lopes S.
    Value Health Reg Issues; 2021 May 22; 24():216-223. PubMed ID: 33857719
    [Abstract] [Full Text] [Related]

  • 15. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators.
    N Engl J Med; 2013 Nov 07; 369(19):1807-18. PubMed ID: 24195548
    [Abstract] [Full Text] [Related]

  • 16. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
    Moreno Guillen S, Losa García JE, Berenguer Berenguer J, Martínez Sesmero JM, Cenoz Gomis S, Graefenhain R, Lopez Sanchez-Cambronero D, Parrondo Garcia FJ.
    Farm Hosp; 2017 Sep 01; 41(5):601-610. PubMed ID: 28847249
    [Abstract] [Full Text] [Related]

  • 17. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E.
    Lancet HIV; 2018 Jul 01; 5(7):e357-e365. PubMed ID: 29925489
    [Abstract] [Full Text] [Related]

  • 18. [Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV.
    Martín-Zaragoza L, Sánchez-Rubio-Ferrández J, Onteniente-González A, Gómez-Bermejo M, Rodríguez-Álvarez SJ, Monereo-Alonso A, Molina-García T.
    Farm Hosp; 2024 Jul 01; 48(4):T171-T175. PubMed ID: 38806363
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG, Chamorro-de-Vega E, Ortega-Navarro C, Alonso R, Herranz-Alonso A, Sanjurjo-Saez M.
    Ann Pharmacother; 2020 Jul 01; 54(7):633-643. PubMed ID: 31910643
    [Abstract] [Full Text] [Related]

  • 20. Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabina/tenofovir-alafenamide among people with HIV.
    Martín-Zaragoza L, Sánchez-Rubio-Ferrández J, Onteniente-González A, Gómez-Bermejo M, Rodríguez-Álvarez SJ, Monereo-Alonso A, Molina-García T.
    Farm Hosp; 2024 Jul 01; 48(4):171-175. PubMed ID: 38448360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.